KAPA

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Kairos Pharma, Ltd.

NYSE MKT | KAPA

1.68

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 17, 2025)

$33.40M

Market Cap

-

P/E Ratio

-0.27

EPS

$2.75

52 Week High

$0.40

52 Week Low

HEALTHCARE

Sector

KAPA Chart

Recent Chart
Price Action

KAPA Technicals

Tags:

KAPA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$160K
Total Revenue $0
Cost Of Revenue $160K
Costof Goods And Services Sold $160K
Operating Income -$2.3M
Selling General And Administrative $1.9M
Research And Development $414K
Operating Expenses $2.3M
Investment Income Net -
Net Interest Income -$859K
Interest Income -
Interest Expense $859K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $295K
Income Before Tax -$2.6M
Income Tax Expense -$2.6M
Interest And Debt Expense -
Net Income From Continuing Operations -$2.6M
Comprehensive Income Net Of Tax -
Ebit -$2.6M
Ebitda -$2.3M
Net Income -$2.6M

Revenue & Profitability

Earnings Performance

KAPA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $5.8M
Total Current Assets $4.2M
Cash And Cash Equivalents At Carrying Value $1.3M
Cash And Short Term Investments $1.3M
Inventory -
Current Net Receivables -
Total Non Current Assets $1.6M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $222K
Intangible Assets Excluding Goodwill $222K
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.9M
Other Non Current Assets -
Total Liabilities $992K
Total Current Liabilities $992K
Current Accounts Payable $992K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $992K
Other Non Current Liabilities -
Total Shareholder Equity $4.8M
Treasury Stock -
Retained Earnings -$8.8M
Common Stock $14K
Common Stock Shares Outstanding $11M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$4M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $160K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $5.1M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$2.6M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$160K
Total Revenue $0
Cost Of Revenue $160K
Costof Goods And Services Sold $160K
Operating Income -$2.3M
Selling General And Administrative $1.9M
Research And Development $414K
Operating Expenses $2.3M
Investment Income Net -
Net Interest Income -$859K
Interest Income -
Interest Expense $859K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $295K
Income Before Tax -$2.6M
Income Tax Expense -$2.6M
Interest And Debt Expense -
Net Income From Continuing Operations -$2.6M
Comprehensive Income Net Of Tax -
Ebit -$2.6M
Ebitda -$2.3M
Net Income -$2.6M

KAPA Profile

Kairos Pharma, Ltd. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Kairos Pharma, Ltd. (KAPA) is a clinical-stage biopharmaceutical company based in Los Angeles, California, dedicated to advancing innovative therapeutics for cancer treatment. With a robust pipeline focused on addressing unmet medical needs, Kairos aims to improve outcomes for patients through its proprietary drug candidates. The company's commitment to research and development positions it strategically within the competitive oncology landscape, making it a compelling prospect for institutional investors seeking exposure to emerging biopharmaceutical innovations.

ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
QBTS
+18.75%
$22.54
NIO
+6.05%
$7.44
SPRC
+142.93%
$4.47
GRAB
-3.48%
$6.10
AAL
+0.56%
$12.48
TSLA
+1.00%
$425.86
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
RGTI
+9.94%
$21.99
SOFI
-1.02%
$27.14
TPIC
-45.91%
$0.12
ADAP
-1.22%
$0.08
PLTR
-1.13%
$168.33
DNN
+1.60%
$2.54
AXDX
-61.36%
$0.03
BBD
+3.11%
$3.31
BMNR
+2.03%
$57.07
INTC
-1.46%
$24.90
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
KDLY
-4.66%
$1.43
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
IONQ
+5.10%
$65.44
NAKA
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.98%
$92.95
RIOT
+0.57%
$17.62
AMZN
-1.03%
$231.62
AIRE
-1.57%
$1.25
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
ABEV
0.00%
$2.36
LDI
+2.70%
$4.55
BINI
-6.96%
$0.06
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
INFY
+3.63%
$17.68
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
JD
+1.52%
$35.24
ATYR
-5.09%
$1.02
GPUS
+6.65%
$0.41
FAAS
-6.04%
$0.09
ITUB
+1.82%
$7.27
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BABA
+2.44%
$166.17
KEY
+0.42%
$18.71
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
IONZ
-10.28%
$4.80
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
GDXD
+1.63%
$1.24
RXRX
-2.68%
$4.71
RAYA
-4.69%
$0.04
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
QBTS
+18.75%
$22.54
NIO
+6.05%
$7.44
SPRC
+142.93%
$4.47
GRAB
-3.48%
$6.10
AAL
+0.56%
$12.48
TSLA
+1.00%
$425.86
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
RGTI
+9.94%
$21.99
SOFI
-1.02%
$27.14
TPIC
-45.91%
$0.12
ADAP
-1.22%
$0.08
PLTR
-1.13%
$168.33
DNN
+1.60%
$2.54
AXDX
-61.36%
$0.03
BBD
+3.11%
$3.31
BMNR
+2.03%
$57.07
INTC
-1.46%
$24.90
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
KDLY
-4.66%
$1.43
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
IONQ
+5.10%
$65.44
NAKA
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.98%
$92.95
RIOT
+0.57%
$17.62
AMZN
-1.03%
$231.62
AIRE
-1.57%
$1.25
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
ABEV
0.00%
$2.36
LDI
+2.70%
$4.55
BINI
-6.96%
$0.06
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
INFY
+3.63%
$17.68
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
JD
+1.52%
$35.24
ATYR
-5.09%
$1.02
GPUS
+6.65%
$0.41
FAAS
-6.04%
$0.09
ITUB
+1.82%
$7.27
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BABA
+2.44%
$166.17
KEY
+0.42%
$18.71
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
IONZ
-10.28%
$4.80
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
GDXD
+1.63%
$1.24
RXRX
-2.68%
$4.71
RAYA
-4.69%
$0.04
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.